MDT

99.02

+1.44%↑

A

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

A

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

A

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

A

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

MDT

99.02

+1.44%↑

A

146.01

+0.06%↑

VEEV

218.99

-0.4%↓

HQY

89.13

+4.04%↑

NEOG

9.46

+2.94%↑

Search

Twist Bioscience Corp

Открыт

СекторЗдравоохранение

41.12 5.19

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

39.15

Макс.

41.46

Ключевые показатели

By Trading Economics

Доход

-48M

-27M

Продажи

3M

99M

Рентабельность продаж

-27.41

Сотрудники

979

EBITDA

3.2M

-21M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+8.44% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

2 февр. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

462M

2.3B

Предыдущая цена открытия

35.93

Предыдущая цена закрытия

41.12

Новостные настроения

By Acuity

50%

50%

151 / 361 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

14 янв. 2026 г., 22:41 UTC

Приобретения, слияния, поглощения

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 янв. 2026 г., 00:00 UTC

Отчет

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 янв. 2026 г., 23:47 UTC

Обсуждения рынка

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 янв. 2026 г., 23:44 UTC

Обсуждения рынка

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 янв. 2026 г., 23:39 UTC

Обсуждения рынка

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 янв. 2026 г., 23:32 UTC

Обсуждения рынка

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 янв. 2026 г., 22:56 UTC

Приобретения, слияния, поглощения

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 янв. 2026 г., 22:53 UTC

Приобретения, слияния, поглощения

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 янв. 2026 г., 22:17 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

14 янв. 2026 г., 22:17 UTC

Обсуждения рынка

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 янв. 2026 г., 22:09 UTC

Отчет

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 янв. 2026 г., 22:08 UTC

Отчет

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 янв. 2026 г., 22:08 UTC

Отчет

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 янв. 2026 г., 21:53 UTC

Приобретения, слияния, поглощения

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 янв. 2026 г., 21:53 UTC

Приобретения, слияния, поглощения

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 янв. 2026 г., 21:52 UTC

Приобретения, слияния, поглощения

WuXi XDC Announces Positive Profit Alert for 2025

14 янв. 2026 г., 21:51 UTC

Приобретения, слияния, поглощения

Citigroup Acting as Financial Advisor to WuXi XDC

14 янв. 2026 г., 21:51 UTC

Приобретения, слияния, поглощения

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 янв. 2026 г., 21:51 UTC

Приобретения, слияния, поглощения

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 янв. 2026 г., 21:50 UTC

Обсуждения рынка
Отчет

Financial Services Roundup: Market Talk

14 янв. 2026 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

14 янв. 2026 г., 21:49 UTC

Приобретения, слияния, поглощения

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 янв. 2026 г., 21:48 UTC

Приобретения, слияния, поглощения

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 янв. 2026 г., 21:48 UTC

Приобретения, слияния, поглощения

WuXi XDC Makes Cash Offer for BioDlink International

14 янв. 2026 г., 21:13 UTC

Обсуждения рынка

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 янв. 2026 г., 20:30 UTC

Обсуждения рынка
Отчет

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 янв. 2026 г., 20:13 UTC

Обсуждения рынка

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 янв. 2026 г., 20:08 UTC

Обсуждения рынка

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 янв. 2026 г., 19:33 UTC

Обсуждения рынка

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 янв. 2026 г., 19:06 UTC

Обсуждения рынка
Отчет

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

8.44% рост

Прогноз на 12 месяцев

Средняя 41.25 USD  8.44%

Максимум 43 USD

Минимум 39 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

5 ratings

5

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

151 / 361Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat